Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Up – Here’s What Happened

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY)’s share price gapped up before the market opened on Thursday. The stock had previously closed at $8.77, but opened at $9.53. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $9.10, with a volume of 1,562 shares trading hands.

Wall Street Analyst Weigh In

Separately, Jefferies Financial Group raised Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 14th. Two equities research analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy”.

Shionogi & Co., Ltd. Unsponsored ADR Stock Up 3.5%

The business’s fifty day moving average price is $9.06 and its two-hundred day moving average price is $9.28. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.00 and a current ratio of 1.14. The firm has a market capitalization of $15.45 billion, a P/E ratio of 9.08, a PEG ratio of 3.16 and a beta of 0.08.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last posted its quarterly earnings data on Monday, August 3rd. The company reported $0.36 earnings per share for the quarter, topping analysts’ consensus estimates of $0.18 by $0.18. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 16.13% and a net margin of 46.67%. The firm had revenue of $1.04 billion during the quarter, compared to analysts’ expectations of $970.69 million. Equities analysts expect that Shionogi & Co., Ltd. Unsponsored ADR will post 0.82 earnings per share for the current fiscal year.

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

Shionogi & Co, Ltd. is a Japan-based research-driven pharmaceutical company headquartered in Osaka. Founded in 1878, the company discovers, develops, manufactures and markets prescription medicines, with a focus on infectious diseases, central nervous system disorders and other areas of unmet medical need.

Shionogi’s portfolio includes Xofluza (baloxavir marboxil), an antiviral treatment for influenza, and F. (fostemsavir), an HIV treatment marketed in certain regions. The company also develops medicines for conditions including pain, psychiatric disorders and other diseases, while pursuing research in areas such as antimicrobial resistance and novel anti-infective therapies.

Shionogi primarily serves the Japanese market and has expanded its international presence through subsidiaries, licensing arrangements and commercial partnerships in North America, Europe and other regions.